Humana stock
Price history
+90.08% over the period1 year: from $236.74 (November 13, 2025) to $450.00 (November 13, 2026), +90.08%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 13, 2026 | $450.00 |
| October 30, 2026 | $414.50 |
| September 30, 2026 | $381.57 |
| August 31, 2026 | $383.23 |
| July 31, 2026 | $363.86 |
| June 30, 2026 | $397.22 |
| May 29, 2026 | $305.42 |
| April 30, 2026 | $236.44 |
| March 31, 2026 | $173.39 |
| February 27, 2026 | $190.54 |
| January 30, 2026 | $195.20 |
| December 31, 2025 | $256.13 |
| November 28, 2025 | $245.77 |
| November 13, 2025 | $236.74 |
At a glance
The company
Offers Medicare Advantage, prescription drug plans, specialty insurance and healthcare services to senior populations in the United States
Latest results
Quarter to September 30, 2026 · EPS -$0.70 (estimate -$1.00)
Dividend
TickerLandia's take on Humana
- Pricier than usual relative to earnings: P/E on the latest fiscal year 46 vs a median of 23 over its last 10 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 39 vs 18 (+114%) in a group of 7.
- Strong point: Market momentum (95/100 in its group). Weak point: Profitability (18/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−1.42% from the 52-week high
Analysts · 26 analysts
Average target$465.13+3.36% vs. price
Buy 16 · Hold 9 · Sell 1 · Buy
TickerLandia Fingerprint: Humana
Compared with similar companies: very strong momentum and very low profitability.
Financials and price compared with 44 companies in related industries (health_services), worldwide. Momentum and risk compared with 883 North American stocks.
Priceaverage56
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 43.3 81 Forward P/E 24.8 74 EV/EBITDA 14.0 57 Price/book 2.87 44 Price/sales 0.35 22 Profitabilityvery low18
How much it earns on revenue and capital.
Metric Value Position in group ROA 3.3% 22 Gross margin 13.0% 22 Net margin 0.8% 13 ROE 6.7% 20 Operating margin 1.8% 15 Earnings stabilityhigh64
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 1.0% 69 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 59 Growthaverage56
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) −17.90% 20 Revenue growth (year over year) +26.10% 92 Average revenue growth (3 years) +11.77% 56 Financial strengthaverage55
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage 5.20 45 Current ratio 1.65 76 Net debt/EBITDAcounts in reverse: lower means more financial strength 2.46 45 Debt/equitycounts in reverse: lower means more financial strength 0.71 55 Dividendaverage48
How much it returns to shareholders, and for how long.
Metric Value Position in group Dividend yield 0.8% 36 Consecutive dividend years 16 years 51 Payout ratio 34.0% 56 Market momentumvery strong95
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +20.56% 92 Relative strength (6 months) +45.32% 93 1-year return +90.08% 97 Distance from 200-day average +41.80% 99 Riskaverage59
How much the price swings.
Metric Value Position in group Volatility (60 days) 37.8% 59 Beta (1 year) 0.54 43 Maximum drawdown (12 months) 42.4% 77
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Humana is pricier than in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), Humana's P/E today is 45.7, above the median of its last 10 fiscal years (23.0; between 14.8 and 50.1 from 2016 to 2025). Humana's P/E (trailing 12 months): 39.0, +114% against the median of a group of 7 similar companies (18.3).
Compared with 7 similar companies
| Metric | Humana | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 39.0 | High | |
| Forward P/E | 26.7 | High | |
| Operating margin | 2.3% | Low | |
| ROE | 6.9% | Low | |
| Debt/equity | 0.76 | High |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Humana. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$40.87B
Latest quarter · Q2 2026
Net income
$694M
Latest quarter · Q2 2026
Quarterly net margin
1.7%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $50.12B
- P/E
- 39.0
- EPS
- $10.28
- Volume
- 65.01K
- Daily trading
- €606.42M
- Dividend yield
- 0.79%
How Humana is changing
All resultsRevenue grew 10.9% a year on average over the last 5 years
Operating margin fell from 4.1% to 2.1%
Profits turn into cash: free cash flow equal to 118% of net income
Returns
Humana returns with dividends
$1,000 invested in Humana 5 years ago, on November 15, 2021, would be worth $1,080 today with dividends reinvested: +8.00% in total, +1.55% per year. On price alone it would be $1,027 (+2.70%).
| Period | Humana | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +7.05% | −3.12% | $1,070 |
| 6 months | +47.61% | +1.58% | $1,476 |
| Year to date | +75.69% | +10.46% | $1,757 |
| 1 year | +92.58% | +12.23% | $1,926 |
| 3 years | −6.11% | +71.41% | $939 |
| 5 years | +8.00% | +61.48% | $1,080 |
| 10 years | +146.38% | +249.40% | $2,464 |
Over the last 6 months it has done better than 85% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment
The chart in detail
Humana: technical analysis
Humana is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 20.1% below its highest close since January 2, 1990 ($563.00, November 3, 2022).
- Trend
- Upward
- RSI (14 sessions)
- 64
- Between 30 and 70
- vs 200-session average
- +41.80%
Support and resistance
Price areas where Humana has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price$450.00
- Support$416.18−7.52%3 touches, last on September 25, 2026
- Support$403.43−10.35%2 touches, last on November 2, 2026
- Support$389.35−13.48%2 touches, last on August 10, 2026
Volatility and risk
Over the last year it has moved less than the S&P 500.
- Beta (1 year) vs S&P 500
- 0.54
- Volatility (60 sessions, annualised)
- 37.8%
- Largest fall in the last year
- −42.36%
Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Humana: seasonality
Average monthly price change over 37 years
Over the last 37 years, the strongest month for Humana has been May: +4.35% on average, positive in 23 years out of 37. The weakest has been March: −2.21% on average, positive in 17 years out of 37. November, the current month, has been positive in 22 years out of 36 (+2.79% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +0.24% | +1.01% | 21 of 36 |
| February | −1.12% | −2.39% | 12 of 37 |
| March | −2.21% | −1.03% | 17 of 37 |
| April | +2.20% | +1.02% | 20 of 37 |
| May | +4.35% | +4.63% | 23 of 37 |
| June | −0.31% | +1.65% | 23 of 37 |
| July | +1.87% | +2.17% | 23 of 37 |
| August | +2.59% | +4.10% | 25 of 37 |
| September | +0.76% | +0.71% | 21 of 37 |
| October | +2.01% | +3.17% | 20 of 37 |
| November | +2.79% | +2.47% | 22 of 36 |
| December | +2.51% | +0.89% | 19 of 36 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Humana and its competitors
Humana's sales are concentrated in the United States, where it sells medical and specialty insurance products. Its Insurance segment centers on Medicare Advantage plans, including wellness programs and chronic care management, along with stand-alone prescription drug plans, Medicare supplements, and dental, vision, life and disability coverage. The company also administers health care arrangements for military retirees and their dependents and runs pharmacy benefit management.
- Headquarters
- Louisville, United States
- Employees
- 67,060
- Founded
- 1961
- Chief executive
- James Rechtin
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| HumanaHUM | $50.12B | 2.3% | 39.0 | +47.61% |
| Cigna GroupCI | $78.26B | 3.8% | 13.1 | −1.23% |
| CenteneCNC | $33.52B | 1.9% | 22.8 | +21.19% |
| Elevance HealthELV | $92.88B | 4.0% | 18.3 | +7.52% |
| CVS HealthCVS | $114.32B | 3.1% | 10.4 | −8.93% |
| UnitedHealth GroupUNH | $365.09B | 5.9% | 23.3 | +1.57% |
Same industry or related industries, similar size. Compare Humana with its competitors · Full profile
